BPC-157

Also called Body Protection Compound-157, Bepecin, PL 147361

2D structure of BPC-157, a chain of 15 amino acids
BPC-157 molecular structureFull structure and downloads
Evidence2/5Almost all animal data. 5 small human studies, none with a clear benefit
Status nowNot FDA-approved. Still not on FDA's compounding list. Under an interim HHS policy, FDA says it won't act against licensed pharmacies that compound the acetate form with a prescription. State rules still apply. Banned in sport at all times.
LatestOctober 28, 2026: HHS said it won't act against single-ingredient BPC-157 acetate made by licensed pharmacies. Blends, such as BPC-157 with TB-500, are excluded.8, 22
NextAdding BPC-157 to the official compounding list needs a formal rule. That process had not started as of Oct 16.17 Full history

BPC-157 is a synthetic chain of 15 amino acids. Almost all the evidence comes from rats, mostly from one lab group. FDA found 5 small human studies. None tested injection under the skin, the way most people use it, and none showed a clear benefit.1 Since October 28, 2026, HHS has said it won't take action against licensed pharmacies that compound it with a prescription. It is still not FDA-approved or on the official compounding list.8

Used in these stacks Wolverine GLOW KLOW

Often paired with TB-500. See BPC-157 vs TB-500

In this guide
  1. Status and summary
  2. At a glance
  3. Where to get it
  4. Molecular structure
  5. What it is
  6. How it works
  7. Evidence map
  8. By goal and route
  9. How it's used
  10. Side effects
  11. Compared with
  12. Stacks
  13. Myths vs evidence
  14. All options and prices
  15. Legal status history
  16. FAQ
  17. References

At a glance

What it isA synthetic 15-amino-acid fragment of a protein first isolated from human gastric juice1
FormsFree base and acetate salt. FDA treats them as different substances. The HHS policy covers only the acetate1, 3
Best evidenceRat studies of tendon healing, gut injury and drug-induced stomach damage1
Human evidence5 small studies. The one randomized trial (ulcerative colitis, by enema) found no significant difference from placebo1
No human evidence forInjection under the skin, oral use, tendon or muscle healing
Legal statusAcetate can be compounded with a prescription under HHS enforcement discretion. Not FDA-approved8, 22
In sportBanned at all times (WADA S0)12, 13
Main risksUnknown in people. FDA cites immune reactions and impurities. A 28-day animal study showed clotting and liver changes1
Typical cost$149 a month for a compounded injection (pre-order)25

Where to get it

MoveWell sells no peptides. All options and prices

Prescription, compoundedSuperpower

BPC-157 injection pre-order at $149 a month. Needs a clinician review and prescription. Shipping targeted for late November.25

See all options
Not launchedHims & Hers

Testing BPC-157 in its own facility. No price or launch date yet.26, 27

Check status
Outside the policyBlends and research vials

Blends like BPC-157 with TB-500 aren't covered by the HHS policy, and neither are "research use only" vials.3

Why

Molecular structure

A straight chain of 15 amino acids with no ring or metal. Three prolines in a row sit near the start.

BPC-157 molecular structure: a chain of 15 amino acids, Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, with the three prolines highlighted

The three prolines (Pro-Pro-Pro)

GGlyEGluPProPProPProGGlyKLysPProAAlaDAspDAspAAlaGGlyLLeuVVal
Sequence
GEPPPGKPADDAGLV
Length
15 amino acids
Formula
C62H98N16O22
Weight
1419.5 g/mol
Acetate
C62H98N16O22 · x(C2H4O2)
CAS
137525-51-0 (free base) · 216441-37-1 (acetate)
FDA UNII
8ED8NXK95P (free base) · PAR2FC72XP (acetate)

Drawn from the sequence FDA lists. Formula and weight are for the free base, as given by FDA and HHS.1, 3

What it is

FDA describes BPC-157 as "a pentadecapeptide fragment of the BPC protein originally isolated from human gastric juice." It was first made in a lab by researchers at the University of Zagreb in the early 1990s.1 The name is a common name, not an official drug name.1

What's sold is synthetic, not taken from stomach juice. FDA found products sold as "BPC-157" in several salt forms and called both the free base and the acetate "not well-characterized."1, 2 An "arginate" salt is sold as a "stable" or oral form. It doesn't appear in any FDA or HHS document we reviewed, and the HHS policy names only the acetate.3

How it works

No one knows for sure. FDA says its "mechanisms of action remain poorly understood," its molecular targets "have not been identified," and dose-response "relationships… have not been established."1

  • Blood vessel growth. Animal papers propose it helps healing by growing new blood vessels.1
  • Growth factor receptors. Papers also propose it raises growth-factor receptors.1
  • Nitric oxide. A third proposed route runs through nitric oxide signaling.1

These are hypotheses from animal and lab work, not measured effects in people.

Evidence map

Each claimed use is graded separately, because the evidence differs by use.

Tendon and ligament

Animal only: rat studies, mostly from one group. An independent 2026 rat study found no significant effect of BPC-157 alone

Gut (colitis, fistulas, NSAID damage)

Animal data. The one human colitis trial found no significant difference from placebo

Knee pain

One uncontrolled chart review of knee injections (FDA counts 17 patients), with no comparison group

Liver and nervous system

Rodent models only

Bladder pain (interstitial cystitis)

One uncontrolled case series of 12. FDA did not report its results in detail

Scale: 5 FDA-approved, 4 strong human, 3 limited human, 2 animal or lab only, 1 anecdotal

Key studies

UseStudyModelFinding
ColitisRuenzi 20051Human RCT n=5380 mg enema daily for 2 weeks. No significant difference from placebo (46 completed)
AbsorptionVeljaca 2002, 20031Human n=24, healthyEnema up to 2 mg/kg for 8 days. Mostly undetectable in the blood
KneeLee & Padgett 20211Human chart review FDA counts 172 to 4 mg into the knee, 1 or 2 doses. Some also got thymosin β4. No control group
BladderLee 20241Human case series n=1210 mg into the bladder wall, once. Results not detailed by FDA
SafetyLee & Burgess 20251Human pilot n=210 mg IV, then 20 mg IV. No serious side effects
OralNCT026372841, 6Registered planned n=42Oral doses vs placebo in healthy people. No results posted; FDA found no publication
TendonBiçer 20265Rat n=32BPC-157 alone was better on paper but not significantly. TB-500 alone was significant
TendonStaresinic 2003; Sikirić 20161RatFaster healing of cut tendons
FistulaKlicek 20081RatBowel-to-skin fistulas about 40% smaller from day 3 and closed by day 28. No tissue analysis
StomachSikirić 19971RatAspirin, diclofenac and indomethacin lesions cut by more than 75%, judged by eye
LiverSikirić 19931RatPrevented liver damage in toxin and stress models when given beforehand
NerveSikirić 2011; Vukojević 20221RodentProtective effects in stroke and spinal cord injury models

Most animal papers in FDA's review come from one Zagreb group (Sikirić, Seiwerth and colleagues). FDA does not comment on this.1 A 2026 scoping review found 67% of the sports-medicine peptide literature was preclinical.11 No human study tested injection under the skin.1

By goal and route

Pick your goal to see what the evidence supports.

InjectionOralTopical
HHS policyCovered, under the skin or into muscle, acetate onlyCovered, acetate only, with documented human bioavailabilityCovered, acetate only
Human evidenceNone under the skin. Knee and IV studies onlyOne trial registered, no resultsNone
Known risksFDA cites immune reactions and impurities. All 3 FDA reports involve injectionsUnknownUnknown
Cost$149 a month (pre-order)Waitlist, no priceNo listing found

Sources: HHS policy terms,3, 23 FDA briefing,1 Superpower pricing.25

How it's used

No human study has worked out a dose for any route people actually use. How the body handles it by mouth, under the skin, in the nose or on the skin is unknown in humans.1, 2

Doses in the human studies

These were milligram doses given by routes few people use: 80 mg a day by enema, 2 to 4 mg into the knee, 10 mg into the bladder, and 10 to 20 mg IV.1

Doses in animals

Rat studies usually used 10 ng/kg or 10 µg/kg, mostly by injection into the belly or in drinking water.1, 5 Per-kilogram human regimens seen online appear to be scaled from these. We found no source that tests them.

In animals it clears fast. Half-life after IV dosing was 5.3 minutes in dogs and 15.2 minutes in rats. About 18% of an injected-into-muscle dose reached the blood in rats, and about 39% in dogs.1 We report these as information, not instruction.

Side effects and who should avoid it

  • Immune reactions. FDA says that given by injection or nose, it "may pose a significant risk for immunogenicity, potentially amplified by aggregation." No immune-response studies exist.1
  • Impurities. Certificates the nominators gave FDA listed 97.8% and 98.34% purity but named no impurities and showed no endotoxin or sterility testing.1
  • Animal toxicology. A 28-day study in rats and dogs, injected into muscle, showed changes in a clotting test (aPTT) and liver signals: ALT, triglycerides, glucose and liver weight. Tissue results were not published. Genetic toxicity tests were negative.1
  • Cancer. This is a theoretical concern, not an FDA finding. BPC-157 is thought to work partly by growing blood vessels, which some worry could help tumors. FDA did not raise this as a safety signal. It said no studies exist to judge cancer risk.1
  • Reported side effects. FDA found 3 reports in its adverse event database (FAERS), all with injected products. FDA said it was unclear whether BPC-157 caused the events. They describe injection-site reactions, shortness of breath needing an ER visit, and darkened skin and gums. One involved a BPC-157 + TB-500 "research purposes only" product.1, 2 In the trials, headache and gas were most common, with no serious events.1
  • Gray-market vials. We found no published test of BPC-157 sold online. "Research use only" products carry no identity, strength or sterility checks.
  • Athletes. Prohibited at all times under WADA S0. The HHS policy doesn't change that.12, 13
  • Pregnancy and breastfeeding. No human data.

Compared with

BPC-157TB-500
What it is15-amino-acid fragment of a gastric juice proteinSynthetic fragment of thymosin β4
Human evidence5 small studies, no clear benefitLess. Human trials used full-length thymosin β4
Rat Achilles study, 2026Not significantSignificant
PCAC vote, Jul 20268–6–18–6–1
HHS routesUnder the skin, muscle, oral, topicalUnder the skin, muscle

Sources: Biçer 2026,5 Superpower guide,7 FDA Law Blog,9 HHS Appendix B.3 Full comparison: BPC-157 vs TB-500

Stacks

Only one BPC-157 combination has been tested, in rats, and it added nothing. All blends fall outside the HHS policy.

Wolverine

Rats only
BPC-157TB-500

No human data. A 2026 rat Achilles study (Biçer, n=32) found the combination gave no added benefit over either alone. TB-500 alone was the only group with a significant gain in tendon strength; the combination improved one tissue score.5 The HHS policy allows one active ingredient, so blends are excluded.3, 23

GLOW

Marketing only
GHK-CuBPC-157TB-500

No human or animal study of the blend. Doses and ratios vary by seller.7 Excluded as a blend.

KLOW

Marketing only
GHK-CuBPC-157TB-500KPV

Same as GLOW. Under the HHS policy KPV is allowed only on the skin or by mouth.3

BPC-157 + GLP-1 drugs

No data
BPC-157semaglutide or tirzepatide

Promoted for GLP-1 stomach side effects. We found no study. FDA's briefing doesn't mention GLP-1 drugs.1

Myths vs evidence

ClaimBPC-157 heals tendons in humans
EvidenceNo controlled human tendon study exists. The tendon data are from rats, and an independent 2026 rat study found no significant effect of BPC-157 alone.1, 5
ClaimIt's safe because it comes from stomach juice
EvidenceIt's a synthetic fragment. FDA cites immune, impurity and aggregation concerns, and liver and clotting changes in a 28-day animal study. Two people have been studied by IV.1
ClaimFDA approved BPC-157 in 2026
EvidenceNo. The advisory vote was non-binding, and FDA staff recommended against it. HHS issued enforcement discretion, which it says is not approval.2, 8, 22
ClaimIt was proven in colitis trials
EvidenceThe one randomized trial (n=53, enema) found no significant difference from placebo. FDA says the data "do not support" use for colitis.1
ClaimOral BPC-157 works like injections
EvidenceThere's no human data on oral absorption or effect. Rectal doses left no detectable drug in the blood.1
ClaimWolverine stacks work better together
EvidenceThe only test, in rats, found no added benefit.5
ClaimResearch-grade is the same as pharmacy-grade
EvidenceResearch products are outside the HHS policy and need no testing certificate. FDA says the label doesn't change how a product is meant to be used.8, 29
ClaimIt's legal for athletes now
EvidenceIt's still on WADA's S0 list, banned at all times.12, 13

All options and prices

MoveWell sells no peptides. Options inside the HHS policy first. Prices checked Oct–Nov 2026

Licensed compounding, with a prescription

Prescription, compoundedSuperpower

BPC-157 injection pre-order at $149 a month. Needs a clinician review and prescription. Shipping targeted for late November.25

See Superpower
ProviderFormPriceStatus
SuperpowerBPC-157 injection$149 a monthPre-order. Clinician review and prescription, US-licensed pharmacy, full refund if not approved. Ships late November25
SuperpowerOral BPC-157Not listedWaitlist25
Hims & HersNot announcedNot listedRunning stability and validation testing. Said in August it was waiting on final FDA rules. No launch confirmed26, 27

Compounded drugs are generally not covered by insurance.10

Blends, outside the policy

ProviderProductPriceStatus

Research use only vials

The HHS policy excludes research chemicals, so we don't list sellers.8, 23 In August 2026 FDA warned five peptide sellers that a "research use only" label doesn't excuse products clearly meant for people.29

FAQ

Is BPC-157 legal?

Single-ingredient BPC-157 acetate can be compounded by a licensed pharmacy with a prescription, under an HHS enforcement policy from October 28, 2026. That is not FDA approval. Blends, research vials and other salts are outside the policy.

Is it FDA-approved?

No. FDA staff recommended against adding it to the compounding list. HHS chose not to enforce against compounding the acetate, and says that is not approval.

Does it work for injuries?

It hasn't been shown in people. The tendon data are from rats. The only human musculoskeletal data are an uncontrolled knee chart review.

Has anyone studied the injection people actually use?

No. None of the 5 human studies FDA found tested injection under the skin.

Is oral BPC-157 the same?

There's no human evidence it is absorbed or works by mouth. The HHS policy requires documented human bioavailability before a pharmacy compounds an oral form.

Is "arginate" or "stable" BPC-157 covered?

No. The policy names only the acetate.

What dose do people use?

No human study has set a dose for any common route. We don't give one.

Can athletes use it?

No. It's on WADA's S0 list and banned in and out of competition.

What is the Wolverine stack?

BPC-157 with TB-500. The only test, in rats, found no added benefit, and blends fall outside the HHS policy.

Does it cause cancer?

No one knows. FDA said no cancer studies exist. Worry about blood-vessel growth and tumors is a theory, not an FDA finding.

References

29 sources, with links
  1. FDA. Briefing document: BPC-157-related bulk drug substances. Pharmacy Compounding Advisory Committee, Jul 23–24, 2026. fda.gov
  2. FDA. July 23, 2026 FDA presentations (PCAC). fda.gov
  3. HHS. 503A peptide enforcement discretion policy, Appendix B. hhs.gov
  4. FDA. Certain bulk drug substances for use in compounding that may present significant safety risks (current as of Apr 22, 2026). fda.gov
  5. Biçer O et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats. Joint Dis Relat Surg 2026;37(3):822–837. DOI 10.52312/jdrs.2026.2951
  6. Superpower. BPC-157 (pentadeca peptide) guide, citing NCT02637284. Link
  7. Superpower. GLOW peptide guide. Link
  8. BakerHostetler. HHS issues enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances (Oct 28, 2026). Link
  9. Hyman Phelps, FDA Law Blog. Peptide-l wave: PCAC approves four bulk drug substances for the 503A list (Jul 2026). Link
  10. AJMC. FDA panel backs 6 peptides for compounding (Jul 31, 2026). Link
  11. AJMC. Unregulated peptides lack purity testing (Oct 5, 2026), citing Tewari K et al., Am J Sports Med 2026, doi:10.1177/03635465261464420. Link
  12. UK Anti-Doping. Major changes to the 2022 Prohibited List. Link
  13. German Sport University Cologne. S0: non-approved substances. Link
  14. FDA Law Blog (Apr 21, 2026). Link
  15. Orrick. FDA announces removal of 12 peptides from Category 2 and schedules PCAC meetings (Apr 16, 2026). Link
  16. Federal Register 2026-07361 (Apr 16, 2026). govinfo.gov
  17. Holland & Knight. Peptides at a crossroads: what wellness providers need to know (Oct 16, 2026). Link
  18. FDA. July 23–24, 2026 meeting of the Pharmacy Compounding Advisory Committee. fda.gov
  19. McDermott Will & Schulte. Bulk-list bound: PCAC backs majority of peptides in two-day public meeting. Link
  20. AmSpa. FDA advisory committee recommends adding six of seven peptides to compounding list. Link
  21. DLA Piper. FDA AdComm recommends adding six peptides to bulk list (Jul 2026). Link
  22. Federal Register public inspection. FR Doc. 2026-22192, HHS notice of availability, docket HHS-OASH-2026-0496. Link
  23. Frier Levitt. HHS peptide enforcement discretion (Oct 28, 2026). Link
  24. FDA Law Blog (Oct 28, 2026). Link; Becker's. HHS allows compounding of 6 unapproved peptides (Oct 28, 2026). Link
  25. Superpower. Peptides pricing page. Link
  26. Becker's. Hims & Hers to sell compounded peptides pending FDA approval (Aug 12, 2026). Link
  27. The Peptide Catalog. Hims & Hers peptide launch and BPC-157 (Aug 2026). Link
  28. HealingMaps. Peptide telehealth (affiliate page, modified Oct 20, 2026). Link
  29. ArentFox Schiff. RUO-ined: five peptide vendors learn research use only is not a legal strategy (Aug 2026). Link

What changed on this page. The earlier version listed a dose and a "For sale" status. Both were wrong. No human study has set a dose,1 and BPC-157 has never been approved for sale. Compounding of the acetate became possible only under the October 28, 2026 HHS policy.8

This page is for education and is not medical advice. BPC-157 is not FDA-approved. Talk to a clinician before using any peptide, especially by injection.